Oncotarget

Research Papers: Chromosome:

Human cancer cells utilize mitotic DNA synthesis to resist replication stress at telomeres regardless of their telomere maintenance mechanism

Özgün Özer, Rahul Bhowmick, Ying Liu and Ian D. Hickson _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:15836-15846. https://doi.org/10.18632/oncotarget.24745

Metrics: PDF 2518 views  |   HTML 3710 views  |   ?  


Abstract

Özgün Özer1, Rahul Bhowmick1, Ying Liu1 and Ian D. Hickson1

1Center for Chromosome Stability and Center for Healthy Aging, Department of Cellular and Molecular Medicine, University of Copenhagen, 2200 Copenhagen, Denmark

Correspondence to:

Ian D. Hickson, email: [email protected]

Keywords: alternative lengthening of telomeres; common fragile sites; RAD52; MiDAS; MUS81; Chromosome

Received: November 02, 2017     Accepted: February 25, 2018      Published: March 23, 2018

ABSTRACT

Telomeres resemble common fragile sites (CFSs) in that they are difficult-to-replicate and exhibit fragility in mitosis in response to DNA replication stress. At CFSs, this fragility is associated with a delay in the completion of DNA replication until early mitosis, whereupon cells are proposed to switch to a RAD52-dependent form of break-induced replication. Here, we show that this mitotic DNA synthesis (MiDAS) is also a feature of human telomeres. Telomeric MiDAS is not restricted to those telomeres displaying overt fragility, and is a feature of a wide range of cell lines irrespective of whether their telomeres are maintained by telomerase or by the alternative lengthening of telomeres (ALT) mechanism. MiDAS at telomeres requires RAD52, and is mechanistically similar to CFS-associated MiDAS, with the notable exception that telomeric MiDAS does not require the MUS81-EME1 endonuclease. We propose a model whereby replication stress initiates a RAD52-dependent form of break-induced replication that bypasses a requirement for MUS81-EME1 to complete DNA synthesis in mitosis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24745